Anjali Ganguli
Corporate Officer/Principal chez SYNDAX PHARMACEUTICALS, INC.
Profil
Anjali Ganguli is currently the Chief Business Officer at Syndax Pharmaceuticals, Inc. She previously worked as the VP-Corporate Development at Regado Biosciences, Inc. from 2014 to 2015.
Dr. Ganguli completed her undergraduate degree at The University of Chicago and holds a doctorate from the University of Michigan.
Postes actifs de Anjali Ganguli
| Sociétés | Poste | Début |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2015 |
Anciens postes connus de Anjali Ganguli
| Sociétés | Poste | Fin |
|---|---|---|
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Corporate Officer/Principal | 01/05/2015 |
Formation de Anjali Ganguli
| University of Michigan | Doctorate Degree |
| The University of Chicago | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
